What Aubrey de Grey's Reported Protocol Might Look Like Clinically

By
Published Updated Last reviewed
Clinical medical image for celebrities aubrey de grey: What Aubrey de Grey's Reported Protocol Might Look Like Clinically

At a glance

  • Who: Aubrey de Grey, Ph.D., biomedical gerontologist and co-founder of the SENS Research Foundation
  • Drug family: Longevity (senolytics, NAD+ precursors, mTOR inhibitors, mitochondrial-targeted compounds)
  • Status: De Grey has confirmed personal experimentation with longevity compounds in podcast appearances. Specific agents and doses are not publicly confirmed in full detail.
  • Clinical angle: The HealthRX Medical Team maps SENS damage-repair categories onto currently available or investigational compounds and evaluates what real prescribing would look like.

The public record on Aubrey de Grey and personal longevity experimentation

Aubrey de Grey spent over two decades as the most visible academic voice arguing that biological aging is an engineering problem with solvable components. Through the SENS Research Foundation and his earlier work at the University of Cambridge, he proposed seven categories of cellular and molecular damage that accumulate with age, each theoretically addressable through targeted repair.

In multiple podcast and conference appearances (including long-form interviews on the Lex Fridman Podcast and Joe Rogan Experience), de Grey confirmed that he personally takes compounds aimed at slowing or repairing age-related damage. He has been candid that his approach is informed by the preclinical literature rather than by FDA-approved indications. He has not, to our knowledge, published a full supplement or drug stack publicly. Any specific agent attributed to him beyond his general confirmation of self-experimentation should be treated as speculated unless a direct, sourced quote establishes otherwise.

This distinction matters. De Grey's public role is as a theorist and fundraiser for longevity research, not as a clinician prescribing protocols. The HealthRX Medical Team treats his confirmed statements as the starting point and layers clinical evidence onto the compound classes he has publicly discussed.

SENS damage categories and their pharmacological translations

The SENS framework identifies seven types of aging damage. Not all have pharmacological solutions today, but several map onto compound classes now in human trials or off-label clinical use. A clinician designing a protocol around SENS principles would consider the following categories most actionable in 2026.

1. Senescent cell accumulation: senolytics

De Grey has publicly discussed the importance of clearing senescent cells, the "zombie cells" that secrete inflammatory signals (the senescence-associated secretory phenotype, or SASP). The senolytic combination of dasatinib plus quercetin (D+Q) is the most-studied regimen in human trials.

A landmark 2019 pilot in patients with idiopathic pulmonary fibrosis used dasatinib 100 mg plus quercetin 1 to 000 mg orally for three consecutive days per week over three weeks. Participants showed improved physical function and reduced SASP markers. Larger trials (the ongoing SEnolytic Therapy in Alzheimer's Disease study, SToMP-AD) are testing intermittent D+Q dosing in neurodegeneration.

What a real prescribing protocol looks like. Dasatinib is an FDA-approved tyrosine kinase inhibitor for chronic myeloid leukemia. Off-label senolytic use typically involves intermittent "hit-and-run" dosing (two to three consecutive days per month or per quarter) rather than continuous administration, because the goal is to trigger apoptosis in senescent cells, not maintain a steady-state drug level. Side effects at oncologic doses include pleural effusion, myelosuppression, and QT prolongation. At senolytic doses given intermittently, reported adverse events have been milder, but long-term safety data in healthy adults remain thin.

Quercetin alone is available over the counter. Its oral bioavailability is low (estimated at 16-24%), and it acts as a weaker senolytic than dasatinib. Phytosome or liposomal formulations may improve absorption.

2. Mitochondrial mutations: NAD+ precursors and mitochondrial support

SENS category two addresses mitochondrial DNA mutations. De Grey has publicly spoken about the role of mitochondrial dysfunction in aging. The most commercially accessible intervention targeting mitochondrial function is supplementation with NAD+ precursors, primarily nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN).

A randomized controlled trial published in Nature Aging showed that NMN at 250 mg/day improved muscle insulin sensitivity and remodeling in postmenopausal women with prediabetes over 10 weeks. NAD+ levels rose in blood, though whether this translates to meaningful mitochondrial DNA repair is unproven.

The HealthRX Medical Team's clinical read. NAD+ precursor supplementation is the most popular "longevity supplement" in the biohacking community, with typical doses of NMN 500-1 to 000 mg/day or NR 300-600 mg/day. The evidence for subjective energy improvement is consistent across trials, but the evidence that these compounds repair mitochondrial mutations (which is the actual SENS target) is weak. They may support mitochondrial function without addressing the underlying genomic damage. A clinician would frame NMN or NR as a mitochondrial support strategy, not a mitochondrial repair strategy, and would monitor NAD+ metabolites via blood panels quarterly.

3. mTOR inhibition: rapamycin

Rapamycin (sirolimus) is the compound with the deepest evidence base in mammalian lifespan extension. The NIA's Interventions Testing Program demonstrated that rapamycin extended median lifespan in genetically heterogeneous mice by 9-14% even when started late in life. De Grey has referenced mTOR pathway inhibition as relevant to several SENS damage categories, particularly loss of tissue homeostasis through impaired autophagy.

Off-label human longevity dosing typically uses 3-6 mg once weekly (compared to the 2-5 mg/day immunosuppressive dose in transplant medicine). The PEARL trial and the AgelessRx RAP study have explored intermittent low-dose regimens. Known risks include impaired wound healing, hyperlipidemia, insulin resistance at higher doses, and immunosuppression. Weekly low-dose protocols aim to capture autophagy-promoting effects while minimizing immunosuppressive exposure, but this is an area where clinical evidence is still accumulating.

Monitoring requirements. Any clinician prescribing rapamycin for longevity should track fasting glucose, HbA1c, lipid panel, and complete blood count at baseline and every 8-12 weeks. Mouth ulcers (aphthous stomatitis) are the most common patient-reported side effect at low doses.

4. Extracellular crosslinks and AGEs

Advanced glycation end-products (AGEs) stiffen tissues, particularly arterial walls. De Grey's SENS framework classifies this as "extracellular crosslinks." No approved drug effectively breaks glucosepane crosslinks in humans yet. Alagebrium (ALT-711) showed modest reductions in arterial stiffness in early trials but development was abandoned. This remains one of the least pharmacologically tractable SENS categories. A clinical protocol in 2026 would default to dietary AGE reduction and cardiometabolic optimization rather than any specific crosslink-breaker drug.

5. Intracellular aggregates: autophagy and emerging therapies

Lipofuscin and other intracellular "junk" accumulate in non-dividing cells like neurons and cardiac myocytes. Beyond rapamycin-induced autophagy (covered above), spermidine is a naturally occurring polyamine that promotes autophagy and has been associated with reduced cardiovascular mortality in epidemiological data. Supplemental doses in human trials range from 1-6 mg/day. This is speculative territory for clinical practice; no prescribing clinician would frame spermidine as a proven therapy.

What a composite "SENS-inspired" clinical protocol might include

The HealthRX Medical Team emphasizes: no published clinical guideline recommends a combined longevity polypharmacy protocol. The following is a reconstruction of what a board-certified longevity physician might consider, compound by compound, for an adult with no contraindications who wished to apply SENS principles pharmacologically.

| Compound | Typical longevity dose | Frequency | Primary SENS target | Evidence level | |---|---|---|---|---| | Dasatinib + Quercetin | 100 mg D / 1 to 000 mg Q | 2-3 consecutive days, quarterly | Senescent cells | Phase 1-2 human data | | NMN or NR | 500-1 to 000 mg NMN or 300-600 mg NR | Daily | Mitochondrial support | RCTs for biomarkers, not hard endpoints | | Rapamycin | 3-6 mg | Weekly | Autophagy / mTOR | Mouse lifespan data; human trials ongoing | | Spermidine | 1-6 mg | Daily | Intracellular aggregates | Epidemiological; small RCTs | | Metformin | 500-1 to 500 mg | Daily | Metabolic / AMPK | TAME trial ongoing (clinicaltrials.gov) |

Metformin appears in this table because the TAME (Targeting Aging with Metformin) trial represents the first FDA-sanctioned attempt to test a drug with "aging" as a primary endpoint. De Grey has commented on metformin's relevance to metabolic aspects of aging, though he has expressed skepticism about its effect size compared to more targeted interventions.

What de Grey's public stance tells us (and what it doesn't)

De Grey has confirmed he experiments on himself. He has publicly stated that he views his own aging as a problem to be solved on the same timeline as the research he funds. What he has not done is publish bloodwork, dosing logs, or a named supplement stack. Specific claims about his exact regimen that circulate in longevity forums are speculated unless traced to a direct, timestamped public statement.

The HealthRX Medical Team's position: de Grey's contribution is theoretical architecture, not clinical protocol design. His SENS framework is a taxonomy of damage, not a prescription. Translating that taxonomy into a supervised medical protocol requires a physician comfortable with off-label prescribing, regular lab monitoring, and honest conversations about the difference between preclinical promise and clinical proof.

Risks and contraindications for a combined longevity stack

Combining dasatinib (a chemotherapy agent), rapamycin (an immunosuppressant), and metformin (a glucose-lowering drug) creates overlapping risks. Immunosuppression from rapamycin layered on dasatinib's myelosuppressive potential could increase infection susceptibility. Metformin combined with rapamycin may produce conflicting effects on insulin signaling. No trial has tested this specific combination in healthy adults. Any clinician building such a protocol would stage compounds sequentially, introducing one at a time with washout monitoring periods of 4-8 weeks.

Frequently asked questions

›
›
›
›
›

References

  • Kirkland JL, Tchkonia T. Senolytic drugs: from discovery to translation. J Intern Med. 2020;288(5):518-536. https://pubmed.ncbi.nlm.nih.gov/32686219/
  • Justice JN, et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine. 2019;40:554-563. https://pubmed.ncbi.nlm.nih.gov/30616998/
  • Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. https://pubmed.ncbi.nlm.nih.gov/35927255/
  • Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392-395. https://pubmed.ncbi.nlm.nih.gov/19587680/
  • Kiechl S, et al. Higher spermidine intake is linked to lower mortality: a prospective population-based study. Am J Clin Nutr. 2018;108(2):371-380. https://pubmed.ncbi.nlm.nih.gov/30405068/
  • Eisenberg T, et al. Cardioprotection and lifespan extension by the natural polyamine spermidine. Nat Med. 2016;22(12):1428-1438. https://pubmed.ncbi.nlm.nih.gov/27841876/
  • FDA Label: Dasatinib (Sprycel). https://accessdata.fda.gov/drugsatfda_docs/label/2023/021986s025lbl.pdf
  • TAME Trial. ClinicalTrials.gov NCT02432287. https://clinicaltrials.gov/ct2/show/NCT02432287
  • Lamming DW, et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science. 2012;335(6076):1638-1643. https://pubmed.ncbi.nlm.nih.gov/25405524/